ascopubs.org

DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody.

A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This ...
ascopubs.org

Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.

Ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Secondary analysis of efficacy and safety results of 4 dosing regimens in the phase II trial I4T-MC-JVDB ...
Finanznachrichten

Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 ...

DS-8201a, given as an intravenous infusion every three weeks, is currently being evaluated in an open-label two-part phase 1 study in patients with advanced/unresectable or metastatic breast cancer, ...
BioWorld

Investigators create breast cancer models with different sensitivities to trastuzumab deruxtecan

Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate used for the treatment of metastatic HER2+ breast cancer that is refractory to anti-HER2 therapy such as T-DM1, however, there is a lack ...
PR Newswire

Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 ...

- Results of first of two-part phase 1 study demonstrate that DS-8201a was well-tolerated with no dose-limiting toxicities - Overall preliminary efficacy results report an objective response rate of ...